This variant is associated with a modified binding affinity of the CDE/CHR repressor, resulting in altered promoter activity and, subsequently, differences in mRNA and survivin protein expression in both normal and cancer cells [23,24,25]. The gene discussed is BIRC5; the disease is cancer.